ETF Series Solutions Trust Range Cancer Therapeutics ETF

The global Cutaneous T-cell lymphoma diagnosis market is expected to grow at a CAGR of 5.2% from 2024 to 2034, driven by advancements in diagnostic technologies such as next-generation sequencing, PCR, and liquid biopsy. The market is expected to reach a valuation of US$ 425.8 million by 2034.

Related tickers: CNCR.

Low-priced stocks could be attractive as these will enable them to buy more shares instead of just a handful of higher-priced shares for the same amount.

Related tickers: CNCR, FXN, CLOU.